Publications by authors named "Helmut Allmeier"

Claim this Profile
A
Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years.
Jean-François Korobelnik, Varun Chaudhary, Paul Mitchell, Se Woong Kang, Helmut Allmeier

Ophthalmologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Intravitreal Aflibercept 2 mg Treatment of Macular Oedema Secondary to Retinal Vein Occlusion in Italy: 24-Month Results from the AURIGA Observational Study.
Maria Oliva Grassi, Andrea Russo, Maria Vadalà, Helmut Allmeier, Tobias Machewitz

Ophthalmologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort.
Clare Bailey, Manju Chandran, Richard Gale, Nirodhini Narendran, James Talks, Helmut Allmeier

Eye (Lond)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration.
Katja Hatz, Aude Ambresin, Martin Schmid, Christian Prünte, Daniel Barthelmes, Helmut Allmeier

J Clin Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Aflibercept in the clinical routine: the AURIGA study : The 24-month results of the German cohort of treatment-naïve patients with diabetic macular edema receiving intravitreal aflibercept].
Michael Ulbig, Christian Karl Brinkmann, Alireza Mirshahi, Hans Hoerauf, Helmut Allmeier

Ophthalmologie· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Aflibercept in a real-world setting: the AURIGA study : 24-month results of the German cohort of treatment-naïve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept].
Joachim Wachtlin, Hakan Kaymak, Hans Hoerauf, Helmut Allmeier, Tobias Machewitz

Ophthalmologie· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.
Jean-François Korobelnik, Varun Chaudhary, Paul Mitchell, Se Woong Kang, Ramin Tadayoni, Helmut Allmeier

Ophthalmol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study.
Audrey Giocanti-Aurégan, Simone Donati, Hans Hoerauf, Helmut Allmeier, Kay D Rittenhouse

Ophthalmol Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study.
Simone Donati, Chang-Hao Yang, Xun Xu, Marco Mura, Audrey Giocanti-Aurégan, Helmut Allmeier

Ophthalmol Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis.
Sebastian Wolf, Frank G Holz, Edoardo Midena, Eric H Souied, George Lambrou, Helmut Allmeier

Ophthalmol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.
Varun Chaudhary, Frank G Holz, Sebastian Wolf, Edoardo Midena, Eric H Souied, Helmut Allmeier

Ophthalmol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
Paul Mitchell, Frank G Holz, Philip Hykin, Edoardo Midena, Eric Souied, Helmut Allmeier

Retina· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.
Jean-François Korobelnik, Michael Larsen, Nicole Eter, Clare Bailey, Sebastian Wolf, Helmut Allmeier

Am J Ophthalmol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma.
Catherine Allaire, Alice Dietrich, Helmut Allmeier, Iveta Grundmane, Grazyna Mazur-Piotrowska

Eur J Ophthalmol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of neutrophil migration and oxygen free radical release by metipranolol and timolol.
Angela Djanani, Nicole C Kaneider, Christian Meierhofer, Daniel Sturn, Stefan Dunzendorfer, Helmut Allmeier

Pharmacology· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis